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Background: Anti-Müllerian hormone (AMH) is a marker of the ovarian reserve with promising prognostic potential
in reproductive medicine. We aimed to evaluate the prognostic ability of AMH for predicting excessive or poor
responses to ovarian stimulation using gonadotrophin-releasing hormone (GnRH) agonist and GnRH antagonist
protocols in patients undergoing medically assisted reproduction (MAR) procedures.
Methods: This retrospective analysis included 623 women who underwent ovarian stimulation for medically
assisted reproduction. AMH level measurements were acquired from all couples within six months of the initiation of
ovarian stimulation.
Results: AMH was significantly correlated with the number of retrieved oocytes, and age was not relevant in a
multivariate regression analysis (unstandardized regression coefficient of 1.130, 95 % confidence interval 0.977-1.283).
AMH was a better predictor of both excessive (>19 oocytes) and poor (<4 oocytes) ovarian response than age (areas
under the curve (AUCs) of 0.882 and 0.816, respectively). When stratified according to the stimulation protocol (a long
GnRH agonist versus a GnRH antagonist protocol), AMH retained its high predictive value for excessive and poor
responses in both groups. Serum AMH levels exhibited a strong correlation with the level of the response to
ovarian stimulation.
Conclusions: AMH is an independent and an accurate predictor of excessive and poor responses to GnRH agonist
and GnRH antagonist protocols for ovarian stimulation.
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GnRH agonistBackground
The accurate prediction of the response to ovarian
stimulation is a valuable diagnostic step in the process of
medically assisted reproduction (MAR). Due to the current
trend of delaying childbearing to a later time in the repro-
ductive lifespan, MAR represents an increasingly important
part of the diagnostics and treatment of subfertile couples.
Although there is a clear relationship between declining
fertility and female age, this relationship is highly variable
[1, 2]. Therefore, a number of endocrine, echographic and
functional ovarian reserve tests have been developed [3].
The aims of these tests are to facilitate the optimisation of* Correspondence: vlai@amis.net
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treatment and to avoid potential unfavourable results
[4]. A significant improvement in the safety of the pa-
tients undergoing assisted reproductive procedures has
been achieved in the last decade, and an unexpected
excessive response associated with a risk of ovarian
hyperstimulation syndrome (OHSS) is no longer an ac-
ceptable outcome. Ovarian reserve tests should help to
identify women who are prone to OHSS while simul-
taneously diagnosing women who are likely to respond
poorly or have a low chance of treatment success.
Many ovarian reserve tests, such as assessments of the
basal follicle stimulating hormone levels (FSH), are part
of currently used routine fertility diagnostic work-ups,cle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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reserve are very limited [3].
In the last decade, anti-Müllerian hormone (AMH)
has emerged as an important marker of ovarian reserve.
AMH is a homodimerous glycoprotein and a member of
the transforming growth factor-β superfamily [5]. In fe-
males, it is secreted exclusively by the granulosa cells of the
ovary. The function of AMH is to inhibit primordial follicle
recruitment and decrease the sensitivity of preantral folli-
cles to FSH [6, 7]. Hence, AMH plays an important role in
the intrafollicular and interfollicular coordination of follicle
development [8]. Due to this function, elevated AMH levels
have been suggested to be responsible for the follicular ar-
rest that has been observed in PCOS patients [9, 10]. AMH
is primarily secreted by the preantral and small antral folli-
cles of sizes up to 6–7 mm [11, 12]. In the larger follicles,
the expression begins to decline until it gradually becomes
undetectable in the large, dominant follicles [12, 13].
AMH is not expressed by atretic follicles or during the
FSH-dependent, final stages of follicular growth. Thus,
the basal levels of AMH more accurately reflect the total
developing follicular cohort [14]. It has been shown that
the serum levels of AMH are more accurately correlated
with the number of antral follicles in the ovary than are
the basal FSH levels [15], and the levels of AMH exhibit
low levels of fluctuation across the menstrual cycle and
across several consecutive menstrual cycles [16–18]. There-
fore, AMH levels can be measured without significant bias
related to the specific timing of the measurement in terms
of the menstrual cycle [18].
However, the value of AMH has primarily been studied
in patients undergoing ovarian stimulation using the long
GnRH agonist protocol. Only a few studies have investi-
gated the value of AMH in in GnRH antagonist cycles
[19–21]. It remains to be confirmed whether AMH has a
comparable ability to predict the ovarian response to the
latter protocol of ovarian stimulation [22]. Our trial was
designed to determine the ability of AMH to predict the
ovarian response following ovarian stimulation with long
GnRH agonist and GnRH antagonist protocols.Methods
Study design
Patients with measured AMH levels who had undergone
ovarian stimulation for IVF or intracytoplasmic sperm
injection (ICSI) procedures were included in the retro-
spectively designed study. All patients from January
2011 to December 2014 were included. Patients were in-
cluded regardless of age, and all indications for IVF or
ICSI treatment were considered as inclusion criteria for the
study. Couples undergoing IVF or ICSI in the natural men-
strual cycle without applied exogenous ovarian stimulation
were excluded from the study. AMH is measured as a partof the routine clinical practice in our unit, and ethical
approval for the study was therefore not required.
AMH measurement
Blood serum AMH assessments were performed as a
part of the routine fertility diagnostics. All measure-
ments were performed with 6 months of the initiation of
ovarian stimulation. This approach has been proven to
assure consistency in the predictive value of AMH [23].
Blood was drawn in serum tubes and stored at −80 °C
until the analysis. All samples were analysed using an AMH
Gen II ELISA kit (Beckman-Coulter, Webster, USA).
The analytical sensitivity of the assay was 0.08 ng/mL,
and the intra-assay and inter-assay coefficients of vari-
ation were than 5.4 % and 5.6 %, respectively. All values
are presented in ng/mL. The conversion factor from
pmol/L to ng/mL is 7.143.
Ovarian stimulation
The patients were treated with either a long GnRH agonist
(triptorelin, Diphereline; Ipsen, France) or a GnRH antag-
onist (cetrorelix, Cetrotide; Merck Serono, Switzerland)
protocol, and these protocols have been described in detail
in our previous publications [24]. The ovarian stimulation
protocol was chosen after discussing the risks and benefits
of each approach with the patient. Patients in their first
ovarian stimulation cycle and those considered to be at
high risk for OHSS were advised to utilise the GnRH
antagonist protocol.
Briefly, all cycles were synchronised using oral contracep-
tive (OC) pre-treatment. The time of OC usage could vary
(minimum of 18 and maximum of 35 days) to synchronise
the menstrual cycles of the patients in the group. In the
case of the long GnRH agonist protocol, seven days before
the last OC pill was taken, the patients began with the ad-
ministration of 0.1 mg triptorelin. In the case of the antag-
onist protocol, ovarian stimulation was initiated 2 days after
the last pill was taken, and 0.25 mg of cetrorelix was started
on a fixed protocol beginning on day 6 of the stimulation.
Ovarian stimulation was initiated by the administration
of a starting dose of 150–300 I.U. of recombinant FSH
(Gonal-F, Merck Serono, Switzerland) or highly purified
HMG (Menopur, Ferring, Switzerland). The dose could
be adjusted on day 6 of the stimulation according to
the level of the ovarian response as demonstrated by
ultrasound. The final oocyte maturation was accomplished
with 6500 I.U. of human chorionic gonadotrophin (hCG)
when three leading follicles of 17 mm were observed on
ultrasound. The oocyte retrieval was planned for 35 h after
the hCG administration.
Main outcomes
The primary goal of our study was to evaluate whether
AMH level measured prior to MAR treatment was
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the abilities of AMH to successfully predict excessive
and poor responses were evaluated. Excessive responses
were defined as more than 19 retrieved oocytes or the
cancellation of the treatment cycle due to a high OHSS
risk before the oocyte collection. This threshold was
adopted in accordance with previously published studies
because such a response is considered to indicate a high
risk of OHSS for the patient [14, 25–27]. The threshold for
poor response was set at <4 oocytes, which complied with
the accepted Bologna criteria, or the exclusion from the
stimulation due to a low response [28]. In the second
part of the study, we aimed to assess whether the pre-
dictive abilities of AMH in terms of excessive and poor
responses differed according to the ovarian stimulation
protocol applied; i.e., the long GnRH agonist protocol
or the GnRH antagonist protocol.
Statistical analysis
The patients’ characteristics (age, number of previous
MAR attempts, duration of stimulation, and total dose of
gonadotrophins required) were compared with respect to
the ovarian stimulation response. Analyses of variance
(ANOVAs) or Kruskal-Wallis tests were used depending
on the distribution of the dependent variable. Additionally,
Spearman rank correlation coefficients were calculated to
evaluate whether the number of retrieved oocytes was cor-
related with AMH and patient age. Next, the variables that
were correlated with the number of retrieved oocytes (age,
AMH and total dose of gonadotrophins) were used to
construct a multivariate linear regression model to identify
and calculate the coefficients for the factors that were in-
dependently related to the number of retrieved oocytes.
Furthermore, to assess the predictive abilities of AMH
for excessive and poor responses, receiver-operating
characteristic (ROC) curves for the AMH levels were
constructed. The sensitivities and specificities were
calculated for selected cut-off levels. To assess possible
differences in the predictive ability of AMH with regard
to the utilised stimulation protocol (long GnRH agonist
versus GnRH antagonist protocol), the area under each
ROC curve was compared using the method described
by DeLong. A value of 0.05 was used as the indicationTable 1 Patient characteristics according to the ovarian response le
No. of retrieved oocytes ≤3 4-10
No. of patients 162 277
Demographics
Age (mean, SD) 36.3 (4.3) 35.0 (4.4)
Previous MAR attempts (median, IQR) 0 (0–3) 1 (0–3)
AMH (median, IQR) 0.40 (0.17- 1.2) 1.35 (0.62- 2.5
IQR interquartile range
SD standard deviationof statistical significance. For the statistical analyses,
the SPSS 20.0 (SPSS Inc.) and STATA 12.0 (StataCorp LP)
software packages were used.
Results
Patients’ characteristics
Overall, 623 women who underwent IVF or ICSI proce-
dures were included in the final analysis. The mean age of
included patients was 34.8 ± 4.6, and the mean number of
retrieved oocytes was 8.4 ± 6.6. Excessive responses were
observed in 46 (7.4 %) women, and 162 (26.0 %) were
categorised as poor responders. Table 1 shows the pa-
tients’ characteristics according to the levels of the ovarian
responses. The levels of AMH and the ages of the patients
were significantly different between the different ovarian
response groups.
In 217 (34.8 %) of the patients, the long agonist protocol
was applied for ovarian stimulation, and the proportions
of patients who underwent the long agonist protocol
were comparable across all of the ovarian response
groups (Table 2). The patients were stimulated for a
median of 10 days with a median total gonadotrophin
dose of 2250 IU. The lo-responding patients required
higher doses of gonadotrophins on average compared with
the normal-responding and the high-responding patients.
AMH and age in relation to ovarian response
The levels of AMH exhibited a strong positive correl-
ation with the number of retrieved oocytes according to
a Spearman’s rank correlation (R = 0.667, p < 0.001). In
contrast, age exhibited a weak but statistically significant
negative correlation with the number of retrieved oocytes
(R = −0.272, p < 0.001). After the construction of a multivar-
iable linear regression model, only AMH and not patient
age was significantly and independently correlated with the
number of retrieved oocytes (unstandardized coefficient
and corresponding 95 % confidence interval of 1.130 and
0.977-1.283, respectively, Table 3).
AMH and its predictive ability for the ovarian response
In the next step of the study, the abilities of AMH to
predict excessive and poor responses were analysed. The
predictive abilities of AMH and age are presented invel
11-19 ≥20 TOTAL p
138 46 623
33.5 (4.8) 32.3 (4.4) 34.8 (4.6) <0.001
0 (0–3) 0 (0–2) 0 (0–3) 0.233
9) 3.10 (1.87- 5.25) 5.88 (3.25- 10.60) 1.49 (0.52-3.29) <0.001
Table 2 Ovarian stimulation parameters according to the ovarian response level
No. of retrieved oocytes ≤3 4-10 11-19 ≥20 TOTAL p
No. of patients 162 277 138 46 623
Protocol used (agonist/antagonist) 47/115 102/175 53/85 15/31 217/406 0.237
Duration of stimulation (median, IQR) 10 (9–12) 10 (9–12) 10 (9–11) 10 (9–11) 10 (9–12) 0.603
Total gonadotrophin dose I.U.
(median, IQR)
2625 (2100–3300) 2250 (1725–2850) 1800 (1425–2400) 1500 (1350–1800) 2250 (1650–2850) <0.001
Outcome
No. of oocytes (median, IQR) 2 (1–3) 6 (5–8) 14 (12–16) 23 (21–26) 6 (3–12) <0.001
IQR interquartile range
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terms of predicting excessive responses; the areas under
the curve (AUCs) and the corresponding 95 % confi-
dence intervals (CIs) were 0.882 (0.840–0.924) and 0.667
(0.587–0.747), respectively (p < 0.001). A similar pattern
was observed for the poor responses; the AUC (95 % CI)
for AMH was 0.816 (0.777–0.855), and that of age was
0.624 (0.575-0.673; p < 0.001). Furthermore, sensitivity
analyses were performed for different AMH cut-off
levels to improve the predictions of excessive and low
responses. The best threshold for predicting an excessive
response was found to be 3.07 ng/mL with a sensitivity of
83.0 % and a specificity of 78.0 %, which corresponded to
positive and negative likelihood ratios (LRs) of 3.8 and 0.2,
respectively, and a positive predictive value (PPV) and
negative predictive value (NPV) of 23.1 % and 98.3 %, re-
spectively. For the prediction of poor response, the thresh-
old was set at 0.66 ng/mL, which resulted in a sensitivity
of 83.7 %, a specificity of 66.7 %, a positive LR of 2.49, a
negative LR of 0.2, a PPV of 46.9 %, and a NPV of 92.1 %.
Finally, we aimed to investigate whether the predictive
ability of AMH was affected by the ovarian stimulation
protocol employed in the treatment. Hence, ROC curves
were constructed for excessive and poor response predic-
tion according to the applied long GnRH agonist or GnRH
antagonist protocol (Fig. 2). These curves revealed that
the predictive value of AMH for excessive responses was
unaltered by the protocol of ovarian stimulation [p = 0.79;
AUCs (95 % CI): 0.876 (0.797-0.956) vs. 0.889 (0.841-
0.938) for the GnRH agonist and antagonist protocols,
respectively]. Similarly, the predictive values for poor
responses were also comparable in both protocols ofTable 3 Linear regression coefficients (95 % confidence
intervals) for the changes in the number of retrieved oocytes
Variable Unadjusted linear regression
coefficient (95 % CI)
P
AMH 1.130 (0.977 to 1.283) <0.001
Age −0.075 (−0.169 to 0.018) 0.114
Total dose of
gonadotrophins
−0.001 (−0.002 to −0.001) <0.001stimulation [p = 0.94; AUC: 0.823 (0.756-0.890) vs.
0.820 (0.775-0.866), respectively].
Discussion
In the present study, we demonstrated a robust correlation
of AMH with the level of ovarian stimulation response
and proved the value of AMH as an independent and
accurate predictor of the excessive and poor responses.
Since the first clinical papers about AMH were published a
decade ago, the use of AMH in reproductive medicine has
become widespread [29] because many reports of the
hormone’s unique characteristics have indicated that it
is useful as a reliable marker of the ovarian reserve [3,
5, 13, 15, 26, 29]. Given these findings, when initiating
ovarian stimulation for assisted reproduction, the ‘one
size fits all’ approach is certainly no longer appropriate
in contemporary clinical practice [30]. The application
of reliable ovarian response predictors is becoming in-
creasingly important. Our study confirmed only a weak
correlation of age with the number of retrieved oocytes,
which is consistent with the results of previously published
trials [31]. AMH is a much more reliable and independent
marker of ovarian response and should thus be considered
when initiating ovarian stimulation treatment. The go-
nadotrophin dose and possible protocol modifications
should be tailored to each individual, and AMH could
be a useful component in these algorithms [22, 32].
Our data revealed high predictive values of AMH for
excessive and poor responses, and such predictive values
are prerequisites of a reliable marker. However, choosing
an appropriate ‘cut-off ’ level requires the assessment of
the eventual benefits versus the harms of the possible
misclassification of patients. Regarding excessive responses,
the threshold of 3.07 ng/mL was shown to result in a sensi-
tivity of 83.0 % and a specificity of 78.0 %. Patients with
AMH levels above this threshold should be considered to
be at high risk of developing OHSS, and more intense
monitoring of ovarian stimulation is warranted. Moreover,
the dose of gonadotrophins should be individualised
regardless of the patients’ age prior to initiating the
first ovarian stimulation cycle. Such optimisation also
includes opting for the GnRH antagonist stimulation
Fig. 1 Receiver-operating characteristic curves for age and Anti-Müllerian hormone for the prediction of excessive (≥20 oocytes) and poor (≤3 oocytes)
responses. (AMH: Anti-Müllerian hormone; ROC area: area under the receiver-operating characteristic curve)
Knez et al. Reproductive Biology and Endocrinology  (2015) 13:58 Page 5 of 7protocol rather than the long GnRH agonist protocol,
which is by itself is related to a lower incidence of
OHSS [33]. Coupled with the possibility of replacing
hCG with a GnRH agonist for final oocyte maturation
triggering and the additional possibility of freezing all
of the developed embryos, this procedure allows for
nearly complete avoidance of the threat of threatening
OHSS [34, 35].
On the opposite end of the spectrum of ovarian stimula-
tion outcomes, we have shown that at the threshold level of
0.66 ng/mL, AMH can serve as a good predictor of poor
responses. However, this finding should be interpreted with
caution. The threshold for a poor response should not
be used as the criterion for denying treatment to a patient
[36] because a substantial portion of patients below this
threshold level are likely to respond well to ovarian stimu-
lation. A false positive test might deter these patients from
successful treatment. Hence, the abnormal ovarian reserveFig. 2 Receiver-operating characteristic curves for the prediction of excessi
applied stimulation protocol. (ROC area: area under the receiver-operatingtest should only be used as a tool to assist the clinician in
counselling the patients about their potential for success
and choice of the optimal treatment plan.
Comparing the cut-off levels determined by our study
to those of previous reports revealed significant variation
in the thresholds that have been determined [14, 25, 26, 31,
37–40]. This variation can largely be attributed to the lack
of standard ‘poor response’ and ‘excessive response’ defini-
tions. However, when assessing these numbers, the method
of AMH detection must also be taken into account. In our
trial, we used the Beckman-Coulter Gen II AMH enzyme
immunoassay, and this method should be used to provide
future standardisation of AMH measurements [41]. Specif-
ically, the source of the significant differences between the
results could be the methodology of the measurements be-
cause studies have shown that AMH levels measured with
the Diagnostic System Laboratories (DSL) assay are ~30 %
lower than those measured with the Gen I immunoassayve (≥20 oocytes) and poor (≤3 oocytes) responses according to the
characteristic curve)
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to levels previously obtained with the Gen I AMH im-
munoassay [41].
Currently, the available data regarding the value AMH
as a prognostic marker of the ovarian response in GnRH
antagonist stimulation cycles remains limited [21, 22].
Considering our data, AMH can be used to predict ex-
cessive and poor responses to GnRH agonist and GnRH
antagonist ovarian stimulation cycles with the same level
of confidence. However, our study is limited by its retro-
spective design, and these findings should be further
confirmed in future, prospectively designed studies.
Conclusions
In conclusion, our data demonstrate the unique prog-
nostic ability of AMH to predict the response to ovarian
stimulation. Because such predictions are of paramount
importance when counselling patients who are undergoing
assisted reproductive procedures, AMH levels should be
determined before embarking on infertility treatments.
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